Cannabis and Cannabinoid Research,
Год журнала:
2018,
Номер
3(1), С. 94 - 107
Опубликована: Апрель 18, 2018
Introduction:
Chronic
cannabis
use
is
associated
with
neuroanatomical
alterations
in
the
hippocampus.
While
adverse
impacts
of
are
generally
attributed
to
Δ9-tetrahydrocannabinol,
emerging
naturalistic
evidence
suggests
cannabidiol
(CBD)
neuroprotective
and
may
ameliorate
brain
harms
use,
including
protection
from
hippocampal
volume
loss.
This
study
examined
whether
prolonged
administration
CBD
regular
users
within
community
could
reverse
or
reduce
characteristic
chronic
use.
Materials
Methods:
Eighteen
participated
an
∼10-week
open-label
pragmatic
trial
involving
daily
oral
200
mg
CBD,
no
change
their
ongoing
requested.
Participants
were
assessed
at
baseline
post-CBD
treatment
using
structural
magnetic
resonance
imaging.
Automated
longitudinal
segmentation
was
performed
assess
volumetric
over
whole
hippocampus
12
subfields.
Results:
No
observed
left
right
as
a
whole.
However,
subicular
complex
(parasubiculum,
presubiculum,
subiculum)
significantly
increased
post-treatment
(p=0.017
uncorrected)
by
1.58%
(Cohen's
d=0.63;
2.83%
parasubiculum).
Heavy
demonstrated
marked
growth
complex,
predominantly
cornu
ammonis
(CA)1
compared
lighter
users.
Associations
between
greater
total
higher
plasma
concentration
evident,
particularly
heavy
Conclusions:
Our
findings
suggest
restorative
effect
on
CA1
subfields
current
users,
especially
those
lifetime
exposure
cannabis.
replication
required
larger,
placebo-controlled
trial,
these
support
protective
role
against
conferred
Furthermore,
outcomes
that
be
useful
adjunct
treatments
for
dependence
therapeutic
range
clinical
disorders
characterized
pathology
(e.g.,
schizophrenia,
Alzheimer's
disease,
major
depressive
disorder).
Pharmaceuticals,
Год журнала:
2023,
Номер
16(4), С. 487 - 487
Опубликована: Март 24, 2023
Cannabidiol
(CBD),
one
of
the
most
promising
constituents
isolated
from
Cannabis
sativa,
exhibits
diverse
pharmacological
actions.
However,
applications
CBD
are
restricted
mainly
due
to
its
poor
oral
bioavailability.
Therefore,
researchers
focusing
on
development
novel
strategies
for
effective
delivery
with
improved
In
this
context,
have
designed
nanocarriers
overcome
limitations
associated
CBD.
The
CBD-loaded
assist
in
improving
therapeutic
efficacy,
targetability,
and
controlled
biodistribution
negligible
toxicity
treating
various
disease
conditions.
review,
we
summarized
discussed
molecular
targets,
targeting
mechanisms
types
nanocarrier-based
systems
management
This
strategic
information
will
help
establishment
nanotechnology
interventions
Experimental and Clinical Psychopharmacology,
Год журнала:
2019,
Номер
28(4), С. 471 - 494
Опубликована: Окт. 31, 2019
Despite
research
advances,
it
remains
unclear
if
long-term,
regular
cannabis
use
harms
cognition
once
intoxication
has
passed.
Our
meta-analysis
aimed
to
investigate
the
association
between
cognitive
functioning
and
long-term
(mean
≥2
years),
≥4
days/week),
recreational
in
adults
during
abstinence
≥12
hr).
We
searched
PubMed,
PsycINFO,
CINAHL,
Scopus,
Dissertations
Theses
International
for
English-language
articles
from
date
each
database
began
until
May
22,
2019.
identified
study
inclusion
by
completing
abstract
full
text
screening
using
predetermined
criteria
Preferred
Reporting
Items
Systematic
Review
Meta-Analysis
guidelines.
classified
performance
into
6
domains
(attention,
executive
function,
learning
memory,
decision
making,
information
processing,
working
memory),
included
a
global
measure.
Effect
sizes
were
calculated
domain
univariate
meta-analyses.
There
30
studies
with
total
849
participants
who
used
(M
=
30.7-years-old,
SD
5.5-years-old)
764
control
30.3-years-old,
5.9-years-old).
Cannabis
was
associated
significant
but
small-magnitude
deficits
cognition,
while
making
had
moderate
deficits.
nonsignificant
group
differences
attention.
duration,
age
of
onset,
prolonged
(≥25
days)
did
not
influence
outcomes,
except
function
analyses
abstinence.
results
suggest
that
is
small
some
domains.
(PsycInfo
Database
Record
(c)
2020
APA,
all
rights
reserved).
Journal of Psychopharmacology,
Год журнала:
2019,
Номер
33(7), С. 822 - 830
Опубликована: Апрель 23, 2019
Background:
Two
major
constituents
of
cannabis
are
Δ
9
-tetrahydrocannabinol
(THC)
and
cannabidiol
(CBD).
THC
is
the
main
psychoactive
component;
CBD
may
buffer
user
against
harmful
effects
THC.
Aims:
We
examined
two
strains
placebo
on
human
brain’s
resting-state
networks
using
fMRI.
Methods:
Seventeen
healthy
volunteers
(experienced
with
cannabis,
but
not
regular
users)
underwent
three
drug
treatments
scanning
sessions.
Treatments
were
containing
(Cann−CBD;
8
mg
THC),
(Cann+CBD;
+
10
CBD),
matched
cannabis.
Seed-based
functional
connectivity
analyses
performed
brain
networks:
default
mode
(DMN;
defined
by
positive
posterior
cingulate
cortex:
PCC+),
executive
control
(ECN;
negative
PCC−)
salience
(SAL;
anterior
insula:
AI+)
network.
Results:
Reductions
in
(relative
to
placebo)
seen
DMN
(PCC+)
SAL
(AI+)
for
both
spatially
dissociable
effects.
Across
entire
network
(AI+),
Cann−CBD
reduced
relative
Cann+CBD.
The
PCC
was
specifically
disrupted
Cann−CBD,
this
effect
correlated
subjective
effects,
including
feeling
‘stoned’
‘high’.
Conclusions:
disrupts
DMN,
a
key
region
involved
experience
intoxication.
restores
disruption
THC,
which
explain
its
potential
treat
disorders
such
as
psychosis
addiction.
Cannabis and Cannabinoid Research,
Год журнала:
2018,
Номер
3(1), С. 94 - 107
Опубликована: Апрель 18, 2018
Introduction:
Chronic
cannabis
use
is
associated
with
neuroanatomical
alterations
in
the
hippocampus.
While
adverse
impacts
of
are
generally
attributed
to
Δ9-tetrahydrocannabinol,
emerging
naturalistic
evidence
suggests
cannabidiol
(CBD)
neuroprotective
and
may
ameliorate
brain
harms
use,
including
protection
from
hippocampal
volume
loss.
This
study
examined
whether
prolonged
administration
CBD
regular
users
within
community
could
reverse
or
reduce
characteristic
chronic
use.
Materials
Methods:
Eighteen
participated
an
∼10-week
open-label
pragmatic
trial
involving
daily
oral
200
mg
CBD,
no
change
their
ongoing
requested.
Participants
were
assessed
at
baseline
post-CBD
treatment
using
structural
magnetic
resonance
imaging.
Automated
longitudinal
segmentation
was
performed
assess
volumetric
over
whole
hippocampus
12
subfields.
Results:
No
observed
left
right
as
a
whole.
However,
subicular
complex
(parasubiculum,
presubiculum,
subiculum)
significantly
increased
post-treatment
(p=0.017
uncorrected)
by
1.58%
(Cohen's
d=0.63;
2.83%
parasubiculum).
Heavy
demonstrated
marked
growth
complex,
predominantly
cornu
ammonis
(CA)1
compared
lighter
users.
Associations
between
greater
total
higher
plasma
concentration
evident,
particularly
heavy
Conclusions:
Our
findings
suggest
restorative
effect
on
CA1
subfields
current
users,
especially
those
lifetime
exposure
cannabis.
replication
required
larger,
placebo-controlled
trial,
these
support
protective
role
against
conferred
Furthermore,
outcomes
that
be
useful
adjunct
treatments
for
dependence
therapeutic
range
clinical
disorders
characterized
pathology
(e.g.,
schizophrenia,
Alzheimer's
disease,
major
depressive
disorder).
